Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 100   

Articles published

SLXP 134.67 -0.47 (-0.35%)
price chart
Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. for Possible ...
If you currently own Salix common stock and purchased it prior to January 28, 2015 or have information to assist in our investigation; or, have any questions or concerns regarding this notice or preservation of your rights, please contact our office ...
Salix Pharma to restate past seven quarters' results
(Reuters) - Salix Pharmaceuticals Ltd said it would restate financial statements for all of 2013 and the first three quarters of 2014, adding to the drugmaker's list of woes.
Salix Pharmaceuticals, Ltd. To Restate Financial Results For Past 7 Quarters  Bidness ETC
Salix Provides Update on Audit Committee Review  MarketWatch
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November
What: Shares of Salix Pharmaceuticals (NASDAQ: SLXP ) , a biopharmaceutical company that develops and acquires drugs designed to treat gastrointestinal diseases, was clobbered in November and fell by 29%, based on data from S&P Capital IQ, after the ...
Salix Pharmaceuticals Given Average Rating of "Hold" by Analysts ...  WKRB News
Related articles »  
Heron Therapeutics Inc (HRTX), La Jolla Pharmaceutical Company (LJPC ...
... track record and will discuss in detail its top three largest holdings in terms of value, which are represented by Heron Therapeutics Inc (NASDAQ:HRTX), La Jolla Pharmaceutical Company (NASDAQ:LJPC), and Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP).
Sale prospects of Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP)
The Jefferies increased the figure of target price which they had put on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), from $123 to $138.
Stock Update: Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)  Street Report
Salix Pharmaceuticals Earns �Buy� Rating from Jefferies Group (SLXP)  Dakota Financial News
Stock in Focus: Salix Pharmaceuticals Ltd. (NASDAQ:SLXP)
[Business WIre] Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (TREND ANALYSIS), announced that the Audit Committee of Salix's Board of Directors (the �Audit Committee�), in consultation with its outside advisors and management, has determined that the ...
Jefferies Rating Disclosure on Salix Pharmaceuticals, Ltd.
Jefferies maintains its rating on Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP). The global brokerage major raises the current price target from $138 per share to $149 per share.
Salix Pharmaceuticals, Ltd CEO Plans To Retire
Salix Pharmaceuticals, Ltd.'s (NASDAQ:SLXP) Chief Executive Officer, Carolyn Logan, has announced plans to retire on January 30, 2015.
Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals  MarketWatch
Salix Pharmaceuticals Ltd. (SLXP) Is Gaining Ground After CEO Retires  Nasdaq
Related articles »  
Exclusive: Salix Pharma working with advisers to explore options - sources
(Reuters) - Salix Pharmaceuticals Ltd SXLP.O, a maker of bowel drugs, is working with investment bank Centerview Partners Holdings LP to explore its options, including a potential sale to a larger drugmaker, according to three people familiar with the ...
Analyst Upgrades: Netflix, Inc., Cree, Inc., and Salix Pharmaceuticals, Ltd.  Schaeffers Research (blog)
Report: Salix Pharmaceuticals Exploring Possible Sale  Benzinga
The Shuman Law Firm Investigates Salix Pharmaceuticals Ltd.
BOULDER, Colo. - The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of Salix Pharmaceuticals Ltd. (�Salix� or the �Company�) (Nasdaq: SLXP). Salix is a Raleigh, NC-based company develops and ...